Abstract
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become cornerstone drugs for the treatment of T2DM. Comprehensive direct comparisons between the effects of different SGLT2 inhibitors are rare in Chinese studies. We aimed to compare the effects of empaglifllozin (EMPA) and dapaglifllozin (DAPA) in Chinese patients with T2DM. METHODS: The study used real-world data for retrospective analysis. The hospitalized patients treated with EMPA or DAPA in our hospital between December 1, 2022 and October 31, 2024 were screened. The matching of 1:1 propensity score (PS) balanced the baseline of EMPA and DAPA groups. To compare the effects of EMPA and DAPA in T2DM patients. RESULTS: The study retrospectively enrolled 5171 patients and finally screened 199 patients (EMPA group) and 179 patients (DAPA group). After 1:1 PS matching, 124 pairs were found successfully. The changes of HbAlc, FBG, HbAl, eAG, TG, TC, HDL-c, LDL-c, AST, ALT, TBiL, DBiL, eGFR and BUN, or the control rates of HbAlc < 7%, FBG < 7 mmol/L, FBG < 6.5 mmol/L, TG, TC, HDL-c, LDL-c, AST, ALT, eGFR, BUN between EMPA and DAPA groups were not significantly different (P > 0.05). There was no significant difference in the incidence of CHD, DN, DR, DPVD, DPN, thyroid nodule, osteoporosis, urinary tract infection, chronic gastritis and oral inflammatory diseases (P > 0.05). The DAPA group showed a significantly lower incidence of MAFLD compared to the EMPA group during the observation period (P < 0.01). CONCLUSIONS: DAPA and EMPA showed parallel effects on glycolipid metabolism, liver and kidney function.